Table 3.

Subtype (IgGx), nature (neutralizing or non-neutralizing), and animal model used to asses therapeutic efficacy of different anti-Ebola mAbs. Relevant references are included.

mAb	Subtype	Neutralizing/non-neutralizing	Animal models used	References
1H3	IgG2a	Neutralizing	Mice, guinea pigs, cynomolgus, rhesus macaques	(Qiu et al., 2012;Qiu et al., 2013)
2G4	IgG2b	Neutralizing	Mice, guinea pigs, cynomolgus, rhesus macaques	(Qiu et al., 2012;Qiu et al., 2013)
4G7	IgG2a	Neutralizing	Mice, guinea pigs, cynomolgus, rhesus macaques	(Qiu et al., 2012;Qiu et al., 2013)
5D2	IgG2a	Non-neutralizing (38%)	Mice, guinea pigs	(Qiu et al., 2012)
5E6	IgG2a	Non-neutralizing	Mice, guinea pigs	(Qiu et al., 2012)
7C9	IgG2a	Non-neutralizing	Mice, guinea pigs	(Qiu et al., 2012)
7G4	IgG1	Non-neutralizing	Mice, guinea pigs	(Qiu et al., 2012)
10C8	IgG2a	Non-neutralizing	Mice, guinea pigs	(Qiu et al., 2012)
KZ52	IgG1	Neutralizing	Mice, guinea pigs, rhesus macaques	(Lee et al., 2008; Parren et al., 2002;)
13F6	IgG2a	Non-neutralizing	Mice, rhesus macaques	(Wilson et al., 2000; Olinger et al., 2012; Zeitlin et al., 2011))
6D8	IgG2a	Non-neutralizing/neutralizing with complement/neutralizing	Mice, rhesus macaques	(Wilson et al., 2000; Shedlock et al., 2010; Olinger et al., 2012; Pettitt et al., 2013)
12B5	IgG1	Non-neutralizing	Mice	(Wilson et al., 2000)
6E3	IgG1	Non-neutralizing	Mice	(Wilson et al., 2000)
13C6	IgG2a	Non-neutralizing/neutralizing with complement/neutralizing 65%	Mice, rhesus macaques	(Wilson et al., 2000; Shedlock et al., 2010; Olinger et al., 2012)
6D3	IgG2a	Non-neutralizing/neutralizing40%	Mice	(Wilson et al., 2000; Shedlock et al., 2010)
133/3.16	IgG1	Neutralizing	Mice	(Takada et al., 2003)
226/8.1	IgG1	Neutralizing	Mice	(Takada et al., 2003)
JP3K11	IgG1	Neutralizing	-----	(Shedlock et al., 2010)
S9		Neutralizing	Mice, guinea pigs	(Marceau et al., 2014)